



UPPSALA  
UNIVERSITET



The University of  
Nottingham

UNITED KINGDOM • CHINA • MALAYSIA

# Tutorial on survival analysis and its application to the assessment of competing risks in clinical data analysis.

Andrew C. Hooker<sup>1</sup>, Joachim Grevel<sup>2</sup>

(1) Uppsala University, Uppsala, Sweden

(2) BAST Inc Ltd, Kington HR5 3DJ UK



# Objectives

- **Part 1: Fundamentals.** The theory of survival analysis including competing risks (Andy).
- **Part 2: Application.** Multistate models and patient benefit (Joachim).

# Acknowledgments


Many of these slides are derived from a set of slides developed by myself and:

- Ulrika Simonsson, Uppsala University
- Mats Karlsson, Uppsala University

# Survival analysis based on time-to-event (TTE)

## Event examples

- Death
- Cardiovascular death
- Drop-out from study
- A side effect (e.g. nausea)
- Progression (cancer, HIV/AIDS)
- Discharge from hospital



# Survival assessment

- **Survival function=  $S(t)$ :** the probability of individual survival beyond time  $t$

$$S(t) = \Pr(T > t)$$

$t$  is some time

$T$  is a random variable denoting the TTE

- **Cumulative distribution function  $F(t)$ :** The probability of individual having an event before, or at, time  $t$

$$F(t) = \Pr(T \leq t) = 1 - S(t)$$

# Non-parametric estimates of $S(t)$


## Kaplan-Meier estimator

$$\hat{S}_{km}(t) = \prod_{i: T_i \leq t} \left(1 - \frac{ne_i}{n_i}\right)$$

$ne_i$  : The number of events at  $T_i$

$n_i$  : The number of individuals who have not had an event or censoring at or before  $T_i$

Implicitly assumes that censored observations will have events in the future



# Models for survival functions

- Often based on the hazard function  $h(t)$ : The instantaneous rate of demise at time  $t$ , conditional on survival to that time

$$h(t) = \lim_{\Delta t \rightarrow 0} \frac{\Pr[(t \leq T < t + \Delta t) \mid T \geq t]}{\Delta t}$$

## To build a likelihood

Dataset		
ID	TIME	DV
1	5.2	1
2	10	0

Probability of surviving beyond a time  $t$  (right censored data,  $t=T$ ,  $DV=0$ ):

$$S(t) = \exp\left(-\int_0^t h(u) \partial u\right)$$

Probability density function for having an event at time  $t$  ( $t=T$ ,  $DV=1$ ):

$$f(t) = \lim_{\Delta t \rightarrow 0} \frac{\Pr(t \leq T < t + \Delta t)}{\Delta t} = h(t)S(t)$$

As long as  $h(t) > 0$   
then  
 $\lim_{t \rightarrow \infty} S(t) = 0$ .  
Censored  
observations will  
have events in the  
future

# Common hazard modeling approaches

- **Semi-parametric:** Cox proportional hazard model

$$h(t) = HR = \frac{h_1(t)}{h_2(t)} = \frac{h_0(t)e^{\beta x_1}}{h_0(t)e^{\beta x_2}} = e^{\beta(x_1 - x_2)}$$

Model Parameters

Covariates

– Estimates hazard ratios (HR) ... relative risk between groups

- **Parametric:** Absolute risk, baseline is modeled.

$$h(t) = h_0(t) \cdot h_a(x, \beta)$$



# Pharmacometric survival analysis?

- Typically fully parametric (modeled baseline)
  - Can more easily handle time-varying covariates (e.g. exposure instead of AUC)

$$h_0(t) = \lambda \alpha (\lambda t)^{\alpha-1}$$

$$h_a(t) = h_0 \cdot \left(1 - \frac{C_p}{C_p + C_{50}}\right)$$

- Clinical trial simulations
- Joint models: Shared parameters with other models
  - E.g. failure to include dropout may introduce bias in parameter estimates
- Repeated events (traditionally not handled in standard analysis)

# Designs can be optimized using these parametric models.

- Optimization of dose levels, number of individuals in each group.
- Adaptive procedures allow for fewer assumptions about model structure.

*The AAPS Journal* (2018) 20: 24  
DOI: 10.1208/s12248-017-0166-5



---

*Research Article*

---

## **Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes**

Yevgen Ryznik,<sup>1,2,4</sup> Oleksandr Sverdlov,<sup>3</sup> and Andrew C. Hooker<sup>2</sup>

<https://doi.org/10.1208/s12248-017-0166-5>

*The AAPS Journal* (2018) 20: 85  
DOI: 10.1208/s12248-018-0242-5



CrossMark

---

*Research Article*

---


## **Implementing Optimal Designs for Dose-Response Studies Through Adaptive Randomization for a Small Population Group**

Yevgen Ryznik,<sup>1,2,4</sup> Oleksandr Sverdlov,<sup>3</sup> and Andrew C. Hooker<sup>2</sup>

<https://doi.org/10.1208/s12248-017-0166-5>

# Goodness-of-fit for parametric survival analysis models

## Visual Predictive Check




Kaplan-Meier plot of data (blue line) and 95% prediction intervals of the Kaplan-Meier plot (green area, 100 simulations).

May also see VPCs for the cumulative distribution function  $F(t)$ :  
 The probability of individual having an event before, or at, time  $t$

$$F(t) = \Pr(T \leq t) = 1 - S(t)$$


# Model building tools

**Hazard assessment:** Hazard based visual predictive check




[Huh, Hutmacher, JPKPD, 2016](#)

**Hazard assessment:** Kernel-Based Visual Hazard Comparison (kbVHC)



[Goulooze et al, AAPS J, 2018](#)

**Covariate assessment:** The Kaplan-Meier Mean Covariate plot (KMMC)



[Hooker, Karlsson, PAGE, 2012](#)

# Other tutorials on survival analysis

[Holford & Lavielle, PAGE, 2011](#)

Citation: *CPT: Pharmacometrics & Systems Pharmacology* (2013) 2, e43; doi:10.1038/psp.2013.18  
© 2013 ASCPT All rights reserved 2163-8306/12  
[www.nature.com/psp](http://www.nature.com/psp)

## TUTORIAL

### A Time to Event Tutorial for Pharmacometricians

Nick Holford<sup>1</sup>


Models for time to event provide the link between standard pharmacokinetic–dynamic models disease progression, and clinical outcome events. The biological basis for events may be expressed quantitatively in terms of a hazard function. This tutorial explains hazards and how doses can be linked to events predicted from hazard functions.

*CPT: Pharmacometrics & Systems Pharmacology* (2013) 2, e43; doi:10.1038/psp.2013.18; advance online publication 15 May 2013

<https://dx.doi.org/10.1038%2Fpsp.2013.18>

# A Hiccup: competing risks

- Assume we want to study time to death attributable to a cardiovascular cause




- Standard methods would separate the two causes and treat events of the other type as censoring events (for Kaplan-Meier and semi-parametric and parametric cause-specific hazard modeling).
  - Assumes that censored observations will have events in the future! (this is wrong)
  - This may overestimate the size of the hazard! (this is bad)

# Cause specific hazard function

ID	TIME	DV
1	5.2	1
2	10	0
3	7.5	0

Cardiovascular death cause specific hazard data



# An solution for competing events: The Cumulative Incidence Function (CIF)


- The probability of experiencing the event k before time t and before the occurrence of a different type of event.

$$CIF_k(t) = \Pr(T \leq t, D = k)$$

- *Non-parametric estimator*

$$\widehat{CIF}_{np,k}(t) = \sum_{i: T_i \leq t} \hat{S}_{km, all\ causes}(t) \frac{ne_{k,i}}{n_i}$$

$ne_{k,i}$  : The number of events of type k at  $T_i$   
 $n_i$  : total number of observations at risk at time  $T_i$



[Austin et al, Circulation, 2016](#)



# Semi-parametric method for modeling the CIF


- Fine-Gray model: A Proportional Hazards Model for the Subdistribution of a Competing Risk
- Proportional Hazard model to describe a hazard derived from CIF

$$h_{k,CIF}(t) = -\frac{d}{dt}\ln(1 - CIF_k(t))$$

- This is called a “subdistribution hazard”: instantaneous risk of failure from the  $k$ th event type in subjects who have not yet experienced an event of type  $k$  (*including* those who have previously experienced a competing event).

# Modeling the subdistribution hazard function parametrically



instantaneous risk of failure from the  $k$ th event in subjects who have not yet experienced an event of type  $k$  (including those who have previously experienced a competing event).



ID	TIME	DV
1	5.2	1
2	10	0
3	7.5	0
3	$\infty$	1

# An alternative approach: Multi-state models for survival analysis

- Potentially a more natural representation of the system
- Events prior to the event(s) of interest may substantially change the risk of the event of interest to occur.



[Beyer et al, Biometrical Journal, 2020](#)

[Ibrahim et al, PAGE 2019](#)

[Krishnan et al, CPT:PSP, 2021](#)  
[Krishnan et al, PAGE, 2021](#)

# Conclusions

- Survival analysis can be very useful but will typically not account for competing events, which may bias the analysis.
- Methods that account for competing events exist and should be used when competing events are present.